StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a research report released on Friday. The firm issued a sell rating on the biotechnology company’s stock.
Separately, Lake Street Capital lowered their target price on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd.
View Our Latest Analysis on EVGN
Evogene Stock Performance
Evogene (NASDAQ:EVGN – Get Free Report) last posted its quarterly earnings data on Thursday, August 22nd. The biotechnology company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The company had revenue of $0.91 million during the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.
Hedge Funds Weigh In On Evogene
An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Further Reading
- Five stocks we like better than Evogene
- Basic Materials Stocks Investing
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.